Latest Licensing Agreements News

Vectus Biosystems advances its lead fibrosis drug VB0004 with validated Phase I safety data and strategic cost reductions, while actively pursuing licensing partnerships in China.

Thrive Tribe Technologies has initiated a corporate restructure focused on revenue growth, appointed a seasoned COO, and rebranded its platform while securing venture debt funding to support expansion.

Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

FirstWave Cloud Technology reported a mixed Q3 FY25 with declining cash reserves and ARR but secured a strategic AWS-funded partnership to accelerate cloud service adoption.

Novonix Limited advances its synthetic graphite production with Riverside commissioning and a new Chattanooga plant site, while winning a preliminary US trade case against Chinese imports and appointing Michael O’Kronley as CEO.

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Cycliq Group Limited reported an 18% revenue increase to $2.9 million for the half-year ending December 2024, driven by higher transaction values and a revamped marketing strategy, despite a modest net loss of $211,214.